Many product and service delivery models have evolved to meet changing market conditions brought on by the world-wide pandemic. Clinical trial logistics are no exception, and the way future trials are conducted may be very different due to lessons learned over the last year.
There is little disagreement that the emergence and spread of COVID-19 has been a game-changing event for the world and for those involved in the development of vaccines.
Historically, companies selling implantable medical devices in Europe have not been required to provide patients with device-specific information. In the event of a medical emergency, not having immediate access to this critical information predisposes the patient to a variety of unnecessary operational risks.